Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis

An “uncorrected” version of the following article was published in the June 2010 issue of MRM. The corrected version of the article is provided here. The publisher regrets the error. Imaging of tumor microvasculature has become an important tool for studying angiogenesis and monitoring antiangiogenic therapies. Ultrasmall paramagnetic iron oxide contrast agents for indirect imaging of vasculature offer a method for quantitative measurements of vascular biomarkers such as vessel size index, blood volume, and vessel density (Q). Here, this technique is validated with direct comparisons to ex vivo micro-computed tomography angiography and histologic vessel measurements, showing significant correlations between in vivo vascular MRI measurements and ex vivo structural vessel measurements. The sensitivity of the MRI vascular parameters is also demonstrated, in combination with a multispectral analysis technique for segmenting tumor tissue to restrict the analysis to viable tumor tissue and exclude regions of necrosis. It is shown that this viable tumor segmentation increases sensitivity for detection of significant effects on blood volume and Q by two antiangiogenic therapeutics [anti-vascular endothelial growth factor (anti-VEGF) and anti-neuropilin-1] on an HM7 colorectal tumor model. Anti-vascular endothelial growth factor reduced blood volume by 36 ± 3% (p < 0.0001) and Q by 52 ± 3% (p < 0.0001) at 48 h post-treatment; the effects of anti-neuropilin-1 were roughly half as strong with a reduction in blood volume of 18 ± 6% (p < 0.05) and a reduction in Q of 33± 5% (p < 0.05) at 48 h post-treatment. Magn Reson Med 63:1637–1647, 2010. © 2010 Wiley-Liss, Inc.